[HTML][HTML] Management of infusion-related reactions following daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple …
Abstract Introduction: Daratumumab (DARA), a human anti-CD38 IgG1κ monoclonal
antibody, showed single agent activity in a phase 1/2 study of patients (pts) with relapsed or …
antibody, showed single agent activity in a phase 1/2 study of patients (pts) with relapsed or …
Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple …
PM Voorhees, B Weiss, S Usmani, H Feng, C Uhlar… - Blood, 2015 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Introduction: Daratumumab (DARA), a human
anti-CD38 IgG1κ monoclonal antibody, showed single agent activity in a phase 1/2 study of …
anti-CD38 IgG1κ monoclonal antibody, showed single agent activity in a phase 1/2 study of …
Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple …
PM Voorhees, B Weiss, S Usmani, H Feng, C Uhlar… - 2015 - ashpublications.org
Abstract Introduction: Daratumumab (DARA), a human anti-CD38 IgG1κ monoclonal
antibody, showed single agent activity in a phase 1/2 study of patients (pts) with relapsed or …
antibody, showed single agent activity in a phase 1/2 study of patients (pts) with relapsed or …